康华生物：公司将积极推进产品研发进程与研发成果落地

Core Viewpoint - Kanghua Biotech has established itself as a comprehensive vaccine enterprise since its founding in 2004, focusing on research, development, and operation in the biopharmaceutical field, and is recognized as the first domestic company to produce and sell human diploid cell rabies vaccines [2] Group 1: Company Overview - The company has accumulated significant advantages in the vaccine industry over more than twenty years [2] - Kanghua Biotech emphasizes the importance of innovative research and development for long-term corporate growth [2] Group 2: Research and Development Platforms - The company has built multiple innovative vaccine platforms, including mRNA vaccine platform, recombinant protein VLP vaccine platform, polysaccharide-protein conjugate vaccine platform, live attenuated vaccine platform, inactivated vaccine platform, and novel vaccine adjuvant platform [2] - Ongoing research projects include a six-valent norovirus vaccine, ACYW135 group meningococcal conjugate vaccine, and herpes simplex virus vaccine [2] Group 3: Future Prospects - The company aims to actively advance the product development process and the realization of research outcomes, with the potential to expand its product pipeline in the future [2]